RituxME

RituxME is a clinical trial of the rituximab ME/CFS research group at the Dept. of Oncology and Medical Physics at Haukeland University Hospital, Bergen, Norway. Senior Consultant Øystein Fluge and Professor Olav Mella are the study supervisors. The final study, published in 2019, showed no overall improvement.

Studies

 * 2016, Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.
 * 2015, B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment
 * 2019, B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial - (Full text)

Learn more

 * 20 Oct 2016, The RituxME and [[CycloME] studies – Ongoing Clinical Research in the ME/CFS Research Group]
 * RituxME website